The biological role of interleukin 6 (IL 6) molecules in human B cell tumorigenesis was studied by using an episomal expression vector, pHEBoSV IL6, to introduce stably the human IL6 gene into human Epstein Barr virus (EBV)-transformed B lymphoblasts . The gene was present in the IL6-transfected cells in a high copy number and was efficiently expressed, resulting in the secretion of consistent levels of 11,6 molecules. The constitutive expression of the IL6 gene led to an altered pattern of growth and to a malignant phenotype, as shown by clonogenicity in soft agar cultures and tumorigenicity in nude mice. These data suggest that the combined action of EBV, which exerts an immortalizing function, and of the growth-promoting activity of IIr6 molecules, can give rise to fully transformed B cell tumors in immunodeficient subjects.
Summary
The biological role of interleukin 6 (IL 6) molecules in human B cell tumorigenesis was studied by using an episomal expression vector, pHEBoSV IL6, to introduce stably the human IL6 gene into human Epstein Barr virus (EBV)-transformed B lymphoblasts . The gene was present in the IL6-transfected cells in a high copy number and was efficiently expressed, resulting in the secretion of consistent levels of 11,6 molecules. The constitutive expression of the IL6 gene led to an altered pattern of growth and to a malignant phenotype, as shown by clonogenicity in soft agar cultures and tumorigenicity in nude mice. These data suggest that the combined action of EBV, which exerts an immortalizing function, and of the growth-promoting activity of IIr6 molecules, can give rise to fully transformed B cell tumors in immunodeficient subjects.
E
BV is a herpes virus that preferentially infects B lymphocytes and induces proliferation, Ig secretion, and immortalization, giving rise to long-term lymphoblastoid B cell lines (LCL)t (1) . EBV infection appears to play a pathogenetic role in the development of endemic Burkitt lymphoma (eBL) and in the recently identified AIDS-associated Burkitt lymphoma (AIDS-BL) (2-4). The nontumorigenic capabilities of LCL suggest that the neoplastic EBVinfected clones present in eBL and AIDS-BL may have acquired a malignant phenotype through additional pathogenetic events, possibly mediated by a deregulated expression of oncogenes (5, 6). As shown for a variety of neoplastic cell types, the continuous proliferation of EBVinfected B cells appears to depend on autocrine secretion of cytokines, including ILA and B cell growth factor-like molecules (7) (8) (9) (10) . IL6 is a glycoprotein secreted by a variety ofcell types, e.g., monocytes, fibroblasts, certain T cell lines, and myeloma cells (11) . Its biological action includes the growth stimulation of plasmacytomas and some EBV lymphoblastoid B cell lines (12, 13) . To investigate whether EBV infection, which exerts a typical immortalizing function, cooperates with the B cell growth-promoting activity of 11,6 in inducing B cell tumorigenesis, we transfected ROHA-9 MC3 cells, an EBV B cell line (8, 9) , with an expression vector that allows a constitutive expression of the 1 Abbreviations used in this paper: BL, Burkitt lymphoma ; eBL, endemic BL; LCL, lymphoblastoid cell lines. human IL6 cDNA. Our results indicate that hyper-expression of an exogenous 11,6 gene in EBVimmortalized B cells results in a dramatic decrease in the requirement for exogenous growth factors with the development ofa fully tumorigenic phenotype.
Materials and Methods
Animals and Reagents . 4-wk-old Swiss female mice were purchased from Charles River Breeding Laboratories (Italy). LPS Escherichia coli 055 :B55 was obtained from Difco Laboratories (Detroit, MI); Plasmid pHEBoSV and pUC9 (3221 were obtained from R. Dalla Favera and P. B. Segal, respectively, hygromycin B was purchased from Boehringer Biochemica (Italy); F(ab)2 fragments of goat antibodies to human or mouse Igs and Leu 16 mAb (anti-CD20) were obtained from Kallested (Austin, TX) and BectonDickinson (Italy), respectively. B6 mAb (anti CD23), W6/32 mAb (anti-human MHC class I), and OKDR (anti-human MHC class II) were purchased from Coulter Immunology (Hialeah, Florida), Seralab (Sussex, England), and Ortho Diagnostics (Raritan, NJ), respectively. rIL6, specific activity 1 x 10' U/mg, was kindly provided by T Kishimoto; goat polyclonal antibody to IL-6 (specific inhibitory activity 102 U/P.l) was the gift of J. Van Damme.
Cells and Culture Conditions. The establishment and characterization of the EBV' ROHA-9 and ROHA-9MC3 cells have been previously reported (8, 9) . Cells were cultured in DME supplemented with 10% vol/vol inactivated FCS (Flow Laboratory) or in HB101 medium (Hang Biologics, Berkeley, CA). Media were additioned with 3 mM glutamine and 10 mM Hepes buffer, pH 7.2 (Gibco Laboratories, Grand Island, NY) . Where indicated, cells were tested for reactivity with fluoresceinated F(ab)2 fragments of goat antibodies to human or mouse Igs and for CD20, CD23, MHC class I and class II expression by flow cytometry (Ortho Spectrum Cytofluorography, Ortho Diagnostics, Italy) . Human monocytes were isolated from PBMC by discontinuous Percoll gradients as described (14) with minor modifications .
Plasmid Construction and Transfection. To generate the pHEBoSV IL6 plasmid, the human 11,6 cDNA was isolated from pUC9 (3221 plasmid (15) by HindIII-SalI digestion and ligated to the HindIIISall sites of pHEBoSV plasmid (5) by standard techniques (16) . Cells were transfected by electroporation (17) . Cells were washed and resuspended in 0.8 ml of Cal* and Mgt'-free PBS (D-PBS) at a concentration of 1.5 x 10'/ml in the presence of 10 Ag of intact pHEBoSV or pHEBoSVIL6 plasmids. Cells were subjected to a single electrical pulse (0 .2 kV, 960 p,FD, 15 ms) using a Bio Rad apparatus, recovered, and cultured for 48 h in DME supplemented with 10% FCS before selection in 300 Wg/ml of hygromycin B. Stable bulk cultures were obtained after 3 wk and subjected to limiting dilution cultures (0 .2 cells/well) to obtain MC3-IL 6 subclones. Cells were routinely cultured in hygromycin B-supplemented medium .
DNA and RNA Analysis . Low molecular weight DNA was isolated according to Hirt (18) , electrophoresed in 0.6% agarose gel, blotted on Gene Screen Plus filters (Du Pont, Italy), and analyzed by Southern blot using an 11,6 cDNA probe 32 P-labeled to a specific activity of 0.8-1 .0 x 109 cpm/lzg by random hexamer method (19) . Hybridization was performed at 65°C in 1 M NaCl, 10% dextran sulfate, 1% SDS, 100,ug/ml denatured salmon sperm DNA. Washing was performed at 65°C as suggested by the manufacturer. Total RNA was extracted by the guanidine-isothiocyanate method, electrophoresed in 1% agarose/2.2 M formaldehyde gels, and then transferred to nylon filters (Gene Screen Plus) by Northern blot . Hybridization and washing were performed as described above. The amounts of RNA were calculated by absorbance at 260 nm and by equalization on agarose gel electrophoresis. After hybridization, the amounts of transferred RNA were checked by staining the filters with 0.04% methylene blue as described by Maniatis et al . (16) .
Cell Growth Assay. To assay the secretion of IL-6 molecules by the transfected cells, supernatant fluids from control and IL6-transfected cells were collected during the logarithmic growth of the cells, dialyzed extensively against DME, filtered (0 .2 ,um), and analyzed for their capacity to sustain the growth of the IL-6-dependent 7TD1 hybridoma cells. The assay was performed essentially as described (20) , except that cold thymidine was omitted from the assay medium . Growth in soft agar was assayed by plating 10 3, 5 x 103, and 1 x 104 cells in 3 ml of medium supplemented with 20% FCS and 0.3% agar in 30-mm culture plates . Cultures were scored for colonies 14 d following seeding. Aggregates of at least 50 cells were considered colonies.
Tumorigenicity in Immunodeficient Mice. Tumorigenicity was assayed essentially as described (21) . Briefly, 4-wk-old Swiss female nude mice (Charles River Breeding Laboratories) were injected subcutaneously with 5 x 106 cells in 0.2 ml of PBS. Tumor diagnosis was confirmed by standard histological examination ; representative tumor samples were analyzed for B cell surface markers by flow cytometry.
Results and Discussion
To obtain a constitutive expression of human IL6 cDNA in EBVinfected lymphoblasts, an appropriate plasmid was developed using the vector pHEBoSV, which carries the 62 Interleukin 6 in Human B Cell Tumorigenesis hygromycin B resistance gene together with the EBV origin ofreplication (oriP) (5, 22). The IL6 cDNA coding sequences were excised from the pUC9 0221 plasmid (15) and inserted downstream to the SV40 promoter element of pHEBoSV plasmid ( Fig. 1 A) . The pHEBoSVIL6 and pHEBoSV control vectors were transfected by electroporation into ROHA-9MC3 EBVB cell line (hereafter referred to as MO) (9) .
Following selection of the transfected cells in medium sup- plemented with hygromycin B (300 wg/ml), bulk cultures of 11,6-transfected MC3 cells (MC3-IL6) or MC3-pHEBoSV were obtained. The MC3-IL6 cells were then subjected to limiting dilution cultures (0 .2 cells/well) to obtain cell clones . The MC3-IL6-9, MC3-IL6-11 bulk cultures and the MC3-IL6-2C4 and MC3-IL6-2A2 clones were randomly selected for the present study; MC3-pHEBoSV bulk cultures served as controls .
The presence of intact vectors in transfected cells was confirmed by Southern analysis of low molecular weight DNA . As shown in Fig. 1 B, the vectors were present as extrachromosomal plasmids with a copy number of N5-10 per cell . No integrated copies of the plasmids were revealed by Southern analysis of genomic DNA (not shown) . The expression of the transfected IL6 cDNA was examined by Northern blots of total RNA from the MC3-IL6 cells by using an 11,6-specific probe. As shown in Fig . 2 A, all the transfected MC3-IL6 clones expressed high amounts of 11,6 mRNAs, whereas the MC3-pHEBoSV control cells showed low levels of specific IL6 mRNA transcripts. Moreover, the MC3-1L6 cells secreted high levels of 11,6 activity, as assayed by the IL-6-dependent 7TD1 hybridoma cell line (20) (see Fig. 2 B) . On a per cell basis, the transcription and secretion of IL6 was higher in MC3-9, MC3-11, MC3-2C4, and MC3- 63 Scala et al.
2A2 cells than in LPS-activated monocytes, while the MC3-pHEBoSV control cells secreted very low amounts of 11,6. To test whether the IL6 expression may lead to an altered requirement for serum growth factors, the MC3-IL6 cells were cultured in serum-free medium at different cell concentrations as previously reported (9) . As shown in Fig . 3 A, the MC3-IL6-9 cells were able to proliferate even when cultured at very low cell concentrations. Under the same culture conditions, the MC3-pHEBoSV control cells failed to elicit a significant proliferation unless the cultures were supplemented with a conditioned medium from MC3-IL6-9 cells. Similar results were obtained using the other IL6-transfected cells (not shown) . This indicated that the requirement for exogenous growth factors was decreased in the IL6-expressing cells, suggesting that the IL-6 molecules could function as autocrine factors for the MC3-IL6 cells . In fact, IL-6 molecules were secreted by the cells and present in culture medium . This possibility was further tested in the experiments illustrated in Fig. 3 (bottom pane . Control and IL6-transfected cells were cultured at 5 x 104/ml cell concentration in HB-101 serum-defined medium (9) and supplemented with optimal concentrations of IL-6. While the control cells retained the capacity to proliferate in response to 11,6, as previously reported for other EBV B cell lines (13), the 11,6-transfected of activation. These latter mechanisms of proliferation would not be affected by antibodies to IL6. Indeed, the gene coding for the IL6 receptor was transcriptionally upregulated in MC3-IL6 cells (Scala, G ., work in progress) .
The altered growth properties of the MC3-IL6 cells were also studied by examining their ability to form colonies in soft-agar cultures, a property common to many naturally occurring B cell neoplasias (23) . As shown in Table 1 , the MC3-IL6 cells exhibited a significant increase in their clonogenic capabilities, while the control MC3-pHEBoSV cells did not form colonies under the same culture conditions, therefore behaving as a common EBVinfected B cell line. In parallel experiments, exogeneous 11,6 (up to 10 3 U/ml) only slightly increased the clonogenic properties of the MC3-pHEBoSV control cells and was uneffective on the growth of the IIr6-transfected MC3 and Daudi cells (not shown) .
The clonogenic potential of transformed cells is often associated with a tumorigenic phenotype (23, 24) . To test whether the MC3-11,6 cells could have acquired a malignant phenotype, we subcutaneously injected various B cell populations into nude mice. As shown in Table 1 , the MC3-IIr6 B cells gave rise to tumors in nude mice, whereas the control MC3-pHEBoSV cells were not tumorigenic . The tumors appeared subcutaneously 10-15 d after the injections, and showed a histological picture of homogeneous infiltrating B cell populations . These cells were characterized by eccen-
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Interleukin 6 in Human B Cell Tumorigenesis tric nucleolated nuclei and large cytoplasms with peripheral condensation (Fig. 4, A, B) . These immunoblastic-like cells were shown to infiltrate periglandular lymphonodes (Fig. 5,   A, B) . In the tumor-bearing mice, however, the secretion of IIr6 by MC3-IIs6 cells could have induced a polyclonal proliferation of mouse B cells that could account for the tumoral masses . To test this possibility, tumor cells from mice injected with MC3-IL6 cells were examined for the expression of CD20, CD23, MHC class I and class II molecules, and for mouse and human surface Igs (p., S, -y, « specificities) . In these experiments, both the original and tumor MC3-IIx 6 cells showed a similar flow cytometry profile (data not shown) . Moreover, analysis of the low molecular weight DNA oftumor cells showed the presence ofpHEBoSV IL6 plasmids (not shown) .
The immortalizing function of EBV infection is not usually associated with tumorigenic capabilities that are often present in naturally occurring EBV+ B lymphomas, including eBL and the recently identified AIDS-BL (2-4). This indicated that other pathogenic events, in addition to EBV infection, may be involved in B cell tumorigenesis . Indeed, the nontumorigenic properties of in vitro infected EBV B cells suggest that additional pathogenic events have occurred in spontaneous EBVrelated B lymphomas .
The growth of neoplastic lymphoid cells of both T and B phenotypes is often dependent upon interleukin-like growth factors that share most of the biochemical and biological properties of the factors secreted and used by normal lymphoid cells (9, 25) . Among these growth factors, 11,6 has been recently identified as a growth and differentiation factor for both normal and transformed B cells (11) . In this study, we attempted to drive an EBV B cell line, MC3, to a malignant phenotype by inserting a constitutively expressed IL6 gene. Present in an episomal replicating plasmid, the gene was stably present in transfected cells with a high copy number and expressed high levels ofthe exogenous IL-6 gene. The resulting MC3-1176 cells showed a donogenic capacity and were tumoriReferences genic in nude mice. These data are consistent with and support the recent observations that transgenic mice carrying a human 11,6 gene develop plasmacytomas (26) , that myeloma cells secrete and use IL6 as autocrine growth factors (27) , and they further suggest that IL-6 molecules play a role in the abnormal growth of neoplastic B cells.
The molecular events sustaining the acquisition of the malignant phenotype are at present unknown . It may be hypothesized that the deregulated expression of IL6 may result in the activation of other pathogenic steps such as oncogene activation. Indeed, hyperexpression ofthe c-myc proto-oncogene in EBV B cells can induce altered growth and tumorigenic properties (5) . These myc-transfected cells also secrete high levels of autocrine growth factors, including IL6 molecules (Scala, G., manuscript in preparation). The in vivo tumorigenicity of the human I1,6-secreting MC3 cells could be expressed in immunodeficient hosts such as nude mice. In this regard, it is noteworthy that variable levels of immunodeficiency are a common feature ofEBVrelated malignancies, including eBL and AIDS-BL (2-4). Our data suggest that the concomitant presence of EBV, which acts as an immortalizing factor, and a deregulated secretion of a cytokine, acting as progression growth factor, can give rise to fully transformed B cell tumors in T cell-deficient subjects .
